公开(公告)号：US20170145009A1

公开(公告)日：2017-05-25

申请号：US15355271

申请日：2016-11-18

Applicant: eFFECTOR Therapeutics, Inc.

Inventor： Paul A. SPRENGELER ,  Seigfried H. REICH ,  Stephen E. WEBBER ,  Justin T. ERNST

IPC: C07D471/04

CPC classification number: C07D471/04 ,  C07D471/10

Abstract: The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula IA or Formula IB, as well as stereoisomers, tautomers or pharmaceutically acceptable salts thereof. For Formula IA and Formula IB compounds A1, A2, A3, A4, W1, W2, Y, X, R1, R2, R3, R4a, R4b, R5a, R5b, R6, R7, R8, R9, R9a, R9b, R10 and subscript n are as defined in the specification. The inventive Formula IA and Formula IB compounds are inhibitors of Mnk and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.